PioLigOn

Company Overview

PioLigOn is at the forefront of peptide, superprotein, and radiotherapeutic drug discovery, leveraging cutting-edge technologies to drive innovation in therapeutic development. By integrating advanced computational methods and novel approaches, PioLigOn is setting new standards in the creation of peptides, superproteins, and radiolabeled therapeutics.

VPDesigner42™: Revolutionizing Peptide Design

The VPDesigner42™ platform is a groundbreaking computational tool specifically designed for non-canonical peptide drug discovery. This platform enables the rapid generation of peptide drug prototypes, with initial designs completed in days. Its modular approach covers a vast chemical space, facilitating the discovery of innovative therapeutic peptides that target a broad range of diseases.

Efficient Drug Discovery Process

PioLigOn’s streamlined workflow moves from in silico design to synthesis and in vitro testing, supporting the efficient development of multiple generations of peptide compounds. This approach enhances both the speed and precision of drug discovery.

superproteins: A New Era of Therapeutics

In addition to peptides, PioLigOn is pioneering the development of superproteins—advanced programmable medicines created from novel, artificial building blocks. These superproteins utilize non-canonical amino acids to evade immune system detection, minimizing immunogenicity and improving delivery and targeting. This innovation promises enhanced treatment effectiveness, new administration methods, and reduced development costs and timelines.

Radiotherapeutics: Targeted Precision

PioLigOn is also making significant strides in radiotherapeutics, developing radiolabeled peptides that offer targeted treatment options. Collaborations with leading companies in this field focus on harnessing the power of radiolabeled compounds for precise and effective cancer therapies. This approach enhances the specificity and efficacy of treatments, providing new solutions for complex medical challenges.

Current Projects and Collaborations

The company is actively engaged in multiple projects involving peptides, superproteins, and radiotherapeutics. Partnerships with pharmaceutical and radiotherapeutics companies focus on developing peptides with non-canonical amino acids, radiolabeled peptides, and advanced therapeutic solutions. PioLigOn’s state-of-the-art laboratory supports in-house discovery, automated synthesis, and comprehensive peptide verification.

Addressing Biologics Challenges

PioLigOn’s focus on peptides, superproteins, and radiotherapeutics addresses key challenges in the biologics market, including limited therapeutic scope, immunogenicity, and high development costs. By introducing innovative technologies and approaches, PioLigOn aims to overcome these barriers and advance the field of biologics.

Business Model and Future Vision

The company operates under a business model that includes contract research, strategic collaborations, and the development of internal drug candidates. PioLigOn’s long-term vision involves expanding its internal projects and continuing to push the boundaries of drug discovery and development in peptides, superproteins, and radiotherapeutics.